May 19, 2022
External forces: rising inflation and higher interest rates have sparked sell-offs in risk equity assets
Investors have numerous reasons to be cautious … although I am attracted to 52-weeks even if “early”
Pre-open indications: 4 Positive Indications, 2 Negative Indications and 1 Puff/Pump/Promote
RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Just the facts … I ask questions and note the indications of what could happen …
May 16, 2022
A scorecard of earnings releases of covered companies - 31 of 35 - so far
The current LPS (loss per share) or net income, cash positions i.e. "runways" is a reflection of this universe's investing "status".
5/16 adding Brainstorm Cell Therapeutics (BCLI), Homology Medicine FIXX) and Biostage (BSTG)
May 18, 2022
On-going elasticity reproduces resistance supported by the thorough lack of confidence and conviction
As I have been writing, “we are renting the upside” keep the lows in your minds-eye; the algorithmic “Pac-men” are lurking! One Tuesday session did NOT mark a sustainable rally; fear DOES forecast a sub-surface reality regarding sustainability.”
Pre-open indications: 3 HITs, 3 MISS and 1 Puff/Pump/Promote
Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read facts supported by real numbers?
May 16, 2022
A scorecard of earnings releases of covered companies - 31 of 35 - so far The current LPS (loss per share) or net income, cash positions i.e. "runways" is a reflection of this universe's investing "status". 5/16 adding Brainstorm Cell Therapeutics (BCLI), Homology Medicine FIXX) and Biostage (BSTG)
May 3, 2022
Earnings’ today – uniQure NV (QURE) – below with more this week … Sage Therapeutics (SAGE) on 5/3, AxoGen (AXGN), Fate Therapeutics (FATE), Global Blood Therapeutics (GBT), Ionis Pharmaceuticals (IONS), MiMedx (MDXG), Editas Medicine (EDIT) and Vericel (VCEL) on 5/4; Sangamo Therapeutics (SGMO) and Ultragenyx Pharmaceuticals (RARE), Intellia Therapeutics (NTLA) on 4/5, BioLife Solutions (BLFS) on 5/9, Agenus (AGEN) on 5/10 and Brainstorm Cell Therapeutics (BCLI) on 5/16 so far.
April 28, 2022
BSTG is also ensnared with a terminal death suit involving Paolo Macchiarini An Italian doctor who made headlines for pioneering windpipe surgery has gone on trial in Sweden, charged with aggravated assault for performing the experimental procedure.
© 2022 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
